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Spinal muscular atrophy (SMA) is a pediatric neuromuscular disease caused by genetic deficiency of the survival
motor neuron (SMN) protein. Pathological hallmarks of SMA are spinal motor neuron loss and skeletal muscle
atrophy. The molecular mechanisms that elicit and drive preferential motor neuron degeneration and death in
SMA remain unclear. Transcriptomic studies consistently report p53 pathway activation in motor neurons and
spinal cord tissue of SMA mice. Recent work has identified p53 as an inducer of spinal motor neuron loss in
severe Δ7 SMA mice. Additionally, the cyclin-dependent kinase inhibitor P21 (Cdkn1a), an inducer of cell cycle
arrest and mediator of skeletal muscle atrophy, is consistently increased in motor neurons, spinal cords, and
other tissues of various SMA models. p21 is a p53 transcriptional target but can be independently induced by
cellular stressors. To ascertain whether p53 and p21 signaling pathways mediate spinal motor neuron death in
milder SMA mice, and how they affect the overall SMA phenotype, we introduced Trp53 and P21 null alleles onto
the Smn2B/− background. We found that p53 and p21 depletion did not modulate the timing or degree of Smn2B/−
motor neuron loss as evaluated using electrophysiological and immunohistochemical methods. Moreover, we
determined that Trp53 and P21 knockout differentially affected Smn2B/− mouse lifespan: p53 ablation impaired
survival while p21 ablation extended survival through Smn-independent mechanisms. These results demonstrate
that p53 and p21 are not primary drivers of spinal motor neuron death in Smn2B/− mice, a milder SMA mouse
model, as motor neuron loss is not alleviated by their ablation.

1. Introduction
The pediatric neuromuscular disease spinal muscular atrophy (SMA)
is the leading genetic cause of infant mortality (Crawford and Pardo,
1996). SMA is an autosomal recessive genetic disorder arising from ho
mozygous loss of the survival motor neuron 1 (SMN1) gene with retention
of at least one copy of the paralogous gene SMN2 (Lefebvre et al., 1995). A
single nucleotide transition in SMN2 impedes splicing of the full-length
SMN2 transcript, yielding very low functional SMN protein levels in
the absence of SMN1 (Lorson et al., 1999). SMN2 copy number varies in
the population and is inversely correlated with SMA disease severity
(Feldkotter et al., 2002). Individuals with SMA experience progressive
weakness, hypotonia, and paralysis of skeletal muscle due to spinal motor
neuron degeneration and cell death (Kolb and Kissel, 2015).

The molecular mechanisms underlying motor neuron loss in SMA
remain unresolved, yet transcriptomic and mechanistic studies have
implicated the tumor suppressor p53 in this process (Jangi et al., 2017;
Murray et al., 2015; Nichterwitz et al., 2020; Simon et al., 2017; Simon
et al., 2019; Staropoli et al., 2015). p53 is a ubiquitously expressed
transcription factor that can initiate pro-survival mechanisms or
apoptosis depending on the severity of the cellular stress (Brady and
Attardi, 2010; Levine and Oren, 2009). p53 is expressed in motor neu
rons of Δ7 SMA mice (Simon et al., 2017). Phosphorylation of p53 serine
18, by p38 MAPK activation, was found to be a death-specific marker
that selectively occurs in vulnerable SMA motor neurons in this model
(Simon et al., 2019). Other transcriptomic studies have identified p53
pathway activation in spinal cord tissue of an antisense oligonucleotidebased, inducible SMA mouse model at 30 days post-induction of the SMA
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phenotype (Jangi et al., 2017; Staropoli et al., 2015) and laser-captured
motor neurons belonging to vulnerable motor pools of pre-symptomatic
Smn2B/− mice (Murray et al., 2015). In these reports, p53 pathway
activation is consistently associated with upregulation of the cyclindependent kinase inhibitor P21 (also known as Cdkn1a) (Jangi et al.,
2017; Murray et al., 2015; Simon et al., 2017; Staropoli et al., 2015), an
inducer of cell cycle arrest (Karimian et al., 2016). Increased P21
expression has further been reported across a wide variety of tissues in
differential gene expression studies using various SMA models (Baumer
et al., 2009; Cherry et al., 2017; Corti et al., 2008; Nichterwitz et al.,
2020; Olaso et al., 2006; Ruggiu et al., 2012; Tadesse et al., 2008; Wu
et al., 2011; Zhang et al., 2008; Zhang et al., 2013). Importantly, p21 can
mediate pro-apoptotic or pro-survival signaling through p53-dependent
or p53-independent mechanisms that are contingent upon the context of
insult and cell type (Gartel, 2005; Gartel and Tyner, 2002). p21 deple
tion studies have not been undertaken in the context of SMA.
Despite consistent reports of p53 pathway activation in SMA models,
inhibition of p53 signaling using genetic and pharmacological methods
has yielded conflicting results regarding therapeutic benefit. Tsai et al.
(2006) ablated Trp53 in ‘Taiwanese’ SMA mice and observed no overall
impact on survival when looking at the overall population of SMA mice
studied; motor neuron loss was not assessed (Tsai et al., 2006). More
recently, Simon et al. (2017) demonstrated that partial genetic and
pharmacological inhibition of p53 did not impart a survival benefit to
Δ7 SMA mice but rescued motor neuron loss (Simon et al., 2017). In
contrast, using an inducible genetic approach, Courtney et al. (2019)
reduced Trp53 transcript abundance in Smn2B/− mice by ~50% and
observed no mitigation of motor neuron loss; survival was not assessed
(Courtney et al., 2019). Taken together, these studies demonstrate that
the transcriptional signature associated with SMA includes the p53
signaling pathway, but whether p53 signaling is necessary to elicit spi
nal motor neuron death across the spectrum of SMA disease severity
remains unclear. This lack of clarity might arise from incomplete Trp53
depletion in the aforementioned study evaluating the impact of p53
reduction in Smn2B/− mice (Courtney et al., 2019).
The Smn2B/− SMA mouse model expresses the hypomorphic Smn2B
allele (Hammond et al., 2010) in conjunction with the Smn null allele
(Schrank et al., 1997); this results in ubiquitously low Smn expression.
The Smn2B allele has a GGA to TTT mutation (the “2B” mutation) in an
exon splicing enhancer site within exon 7, disrupting exon 7 inclusion in
the mature Smn transcript (DiDonato et al., 2001). Smn2B/− mice have a
slightly milder disease course and are longer-lived than the more
commonly utilized Δ7 SMA mouse model (Bowerman et al., 2012;
Gogliotti et al., 2013; Le et al., 2005; Quinlan et al., 2019).
Here, we determine whether p53 and p21 are primary mediators of
spinal motor neuron loss in less severe SMA mice, using the Smn2B/−
model. We demonstrate that partial and complete Trp53 and P21 abla
tion does not modulate the timing of motor unit loss in Smn2B/− mice.
Furthermore, we find that p53 and p21 depletion does not rescue spinal
motor neuron death or body weight deficits characteristic of Smn2B/−
mice, but differentially modifies their survival. p53 ablation impaired
survival while p21 ablation enhanced survival through mechanisms that
did not alter Smn levels. Since p21 signaling drives skeletal muscle at
rophy (Bongers et al., 2015; Fox et al., 2014), we investigated whether
extended survival of P21-depleted Smn2B/− mice was caused by atten
uated muscle atrophy, but this was not the case. Taken together, these
results demonstrate that neither p53 nor p21 signaling pathways are
primary drivers of spinal motor neuron loss in milder SMA mice, such as
the Smn2B/− model, as motor neuron death proceeds with the same de
gree and swiftness in their absence.

National Institutes of Health Guide for Care and Use of Laboratory An
imals. Approval from Northwestern University’s Institutional Animal
Care and Use Committee was obtained for all experiments performed in
this study.
2.2. Animal housing and husbandry
Mice were kept in a controlled vivarium in a 12:12 h light-dark
photoperiod and monitored for health. SMN2+/+; SMNΔ7+/+; Smn+/−
mice were purchased from The Jackson Laboratory (Jax stock no.
005025) and maintained in our colony. Intercrossing SMN2+/+;
SMNΔ7+/+; Smn+/− mice generated Δ7 SMA mice (genotype: SMN2+/+;
SMNΔ7+/+; Smn− /− ) and control mice (genotypes: SMN2+/+; SMNΔ7+/
+
; Smn+/+ and SMN2+/+; SMNΔ7+/+; Smn+/− ). End-stage Δ7 SMA mice
were euthanized when functional death endpoints were reached (20%
loss of body weight, inability to right within 30 s after placement in
supine position, and/or visible distress).
The official name of the Smn null allele (Smn− ) reported by Schrank
et al. (1997) and used here on a congenic C57BL/6 background is FVB.
Cg-Smn1tm1Msd (Schrank et al., 1997) (Jax stock no. 006214). The official
name of the Smn2B allele is B6.129(Cg)-Smn1tm1.1Cdid/J; it was used in
these studies on a congenic C57BL/6 background (Jax stock no. 34285).
This allele was generated from the progenitor line Smn2B-Neo (B6.129Smn1tm1Cdid) by removal of the flox-neo cassette (Hammond et al.,
2010). Mice expressing the Trp53 null allele (Trp53− ) (Jacks et al., 1994)
or the P21 null allele (P21− ) (Deng et al., 1995) on congenic C57BL/6 J
backgrounds (official names Trp53tm1Ty and Cdkn1atm1Led, respectively)
were obtained from The Jackson Laboratory (Jax stock no. 002101 and
016565, respectively) and bred to Smn2B/2B and Smn+/− mice. Smn2B/+
(control) and Smn2B/− (SMA) mice expressing Trp53+/+, Trp53+/− or
Trp53− /− were generated by crossing Smn+/− ; Trp53+/− or Smn+/− ;
Trp53− /− mice with Smn2B/2B; Trp53+/− or Smn2B/2B; Trp53− /− mice.
Similarly, Smn2B/+ and Smn2B/− mice expressing P21+/+, P21+/− or
P21− /− were generated by breeding Smn+/− ; P21+/− or Smn+/− ; P21− /−
mice with Smn2B/2B; P21+/+, Smn2B/2B; P21+/− , or Smn2B/2B; P21− /−
mice. At weaning, Smn2B/− mice were weaned with at least one Smn2B/+
littermate (if available) and received moist chow three times weekly to
assist with food and water intake. Both male and female mice were
included in experiments. However, more male mice homozygous for the
Trp53 null allele were included compared to females of the same ge
notype, due to sex ratio distortion arising from embryonic-lethal
developmental defects common to female Trp53 null mice (Hu et al.,
2008).
2.3. Genotyping
DNA extracted from mouse tail biopsies was genotyped using
multiplex PCR. Genotyping the Smn null allele and Smn2B allele was
done as previously described (Gogliotti et al., 2012; Schrank et al.,
1997). The Trp53 null allele was genotyped using a common primer (5′ TGG ATG GTG GTA TAC TCA GAG C), a mutant forward primer (5’-CAG
CCT CTG TTC CAC ATA CAC T), and a wild type forward primer (5′ -AGG
CTT AGA GGT GCA AGC TG). The product sizes of the wild type and
knockout alleles were 321 bp and ~ 110 bp, respectively. The P21 null
allele was genotyped using a common forward primer (5′ -GTT GTC CTC
GCC CTC ATC TA), a wild type reverse primer (5’-GCC TAT GTT GGG
AAA CCA GA), and a mutant reverse primer (5’-CTG TCC ATC TGC ACG
AGA CTA). The sizes of the wild type and knockout amplicons were
240 bp and 447 bp, respectively. The cycling conditions for PCR geno
typing of both Trp53 and P21 null alleles were: 94 ◦ C/30 s, 63 ◦ C/45 s,
72 ◦ C/45 s, 35 cycles.

2. Methods

2.4. Assessment of Smn2B/− mouse weight and survival

2.1. Ethics statement

Smn2B/− mice were monitored daily for survival and weight. Func
tional death was defined as the inability to right within one minute of

All experiments were performed in accordance with the U.S.
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placement in a supine position. If functional death endpoint was
reached, that day was noted as the date of death in survival analysis.
Mice that died perinatally, or from a cage flood, or were unexpectedly
missing from the cage, were excluded from survival analyses. In the
event of cage flooding, weight measurements obtained the same day and
one day after the event were eliminated from weight analysis. Crossing
the Trp53 or P21 null allele onto the Smn2B/− line frequently produced
runts (both in control and SMA mice). Runts were identified as mice
weighing less than either 1.9 g at P5 or 3.5 g by P10. These thresholds
were selected because they are greater than two standard deviations
below the historical mean body weight of Smn2B/− mice at P5 and P10,
respectively. All runts, except those so severely runted that death
occurred prior to postnatal day (P)6, were included in survival and
weight analyses.

each group analyzed ranged from N = 3–4 samples. Samples with Cq
values >35 cycles were considered as having no detectable expression.
Data was analyzed using the ΔΔCT method. TaqMan primer/probe as
says used in this study were: Gapdh (4352339E), Actin (4352341E),
Trp53 (Mm01731290_g1), Cdkn1a (Mm04205640_g1), Fas (Mm0120
4974_m1), Pmaip1 (Mm00451763_m1), Fasl (Mm00438864_m1).
2.7. Electrophysiological studies
Electrophysiological measurements were recorded from mice at ages
P12-P18. These included controls and Smn2B/− mice that were wild type,
heterozygous or homozygous null for either Trp53 or P21. Trp53 groups
were studied at P12, P14, and P17-18 and P21 groups were studied at
P14. Compound muscle action potential (CMAP) and motor unit number
estimation (MUNE) were measured using a portable electrodiagnostic
system (Synergy EMG machine; Natus Neurology, Middleton, WI) as
previously described in detail (Arnold et al., 2014; Quinlan et al., 2019).
In brief, insulated monopolar needles were inserted into the proximal
hindlimb to provide sciatic nerve stimulation. Ring electrodes were
positioned over the proximal triceps surae muscle to record CMAP
amplitude; a reference electrode was placed over the metatarsals. A
disposable strip electrode (CareFusion, Middleton, WI) was placed on
the tail (or contralateral limb) to serve as the ground electrode. The
sciatic nerve was stimulated with single square-wave pulses of 0.1-ms
duration. Supramaximal responses were generated maintaining stim
ulus currents ˂ 10 mA; baseline-to-peak and peak-to-peak CMAP ampli
tude measurements were obtained.
MUNE was measured using an incremental stimulation technique.
Average single motor unit potential (SMUP) amplitude was calculated
from 10 incremental responses obtained using submaximal stimulation.
The first increment (the minimal all-or-none SMUP response) was
evoked by delivering 1-Hz square-wave stimulations at an intensity
between 0.21 and 0.70 mA. Stimulation intensity was adjusted in 0.03mA steps to obtain subsequent incremental responses; incremental re
sponses were distinguished visually in real time to obtain nine addi
tional increments. To be accepted, each increment was required to be: 1)
observed for a total of three duplicate responses; 2) visually distinct from
the prior response; and 3) at least 25 μV greater than the prior response.
The peak-to-peak amplitude of each individual incremental response
was calculated by subtracting the amplitude of the prior response.
Average peak-to-peak SMUP amplitude was defined as the mean peakto-peak amplitude of the 10 incremental values. Maximum CMAP
amplitude (peak-to-peak) was divided by average peak-to-peak SMUP
amplitude to yield the estimated number of motor units (MUNE).

2.5. Western blotting
Tissues were dissected and snap frozen on dry ice or liquid nitrogen.
Total protein was extracted from homogenized tissues using RIPA buffer
supplemented with Halt Protease Inhibitor Cocktail (Thermo Scientific,
cat. # 87786), resolved by 10% or 4–12% Bis-Tris polyacrylamide gels
using MOPS or MES running buffer, and subsequently transferred to
nitrocellulose membranes for western blotting. Ponceau S was applied to
visualize total transferred protein levels then the membranes were
blocked overnight at 4 ◦ C in Odyssey® Blocking Buffer in PBS (LI-COR,
cat. #927–40,000). Membranes were probed with primary antibodies
for either two hours (Smn, β-tubulin) or overnight at 4 ◦ C (p53, p21,
β-actin, β-tubulin) followed by corresponding secondary antibody in
cubations for one hour at room temperature. Detection was performed
using the LI-COR Odyssey Imaging System. Densitometric quantification
was performed using ImageJ software. Details for primary and second
ary antibodies utilized in these studies were as follows: p53 immuno
blots used 40 μg/sample, rabbit anti-p53 antibody (1:1000, Leica
Novacastra, cat. #NCL-L-p53-CM5p), rabbit anti-β-actin antibody
(1:1000, LI-COR, cat. #926–42,210) and goat anti-rabbit IgG IRDye®
680RD antibody (1:5000, LI-COR, cat. #926–68,071); Smn immuno
blots used 22 μg/sample, mouse anti-Smn antibody (1:2500, BD Bio
sciences, cat. #610646), goat anti-mouse IgG IRDye® 800CW antibody
(1:5000, LI-COR, cat. #926–32,210), rabbit anti-β-tubulin antibody
(1:5000, Cell Signaling, cat. #2128), and goat anti-rabbit IgG IRDye®
680RD antibody (1:5000, LI-COR, cat. #926–68,071); p21 immunoblots
used 48–50 μg/sample, mouse anti-p21 antibody (1:1000, Santa Cruz,
cat. # sc-6246), goat anti-mouse IgG IRDye® 800CW antibody (1:5000,
LI-COR, cat. #926–32,210) and either rabbit anti-β-tubulin or β-actin
antibody with corresponding secondary antibody as noted above.
Specificities of p53 and p21 antibodies were confirmed using protein
lysates obtained from Trp53 and P21 null tissues. Positive control lysates
for p53 and p21 that were included on immunoblots were generated
from GL26-luc cells treated for 12–24 h with 1 μM doxorubicin.

2.8. Spinal cord immunostaining
Spinal cord immunofluorescence experiments utilized P16 Smn2B/+
and Smn2B/− mouse cohorts. After euthanasia, spinal cords were exposed
by dorsal laminectomy and spinal columns were isolated. Spinal col
umns were fixed overnight at 4 ◦ C in 2% paraformaldehyde, rinsed in
PBS, and cryoprotected in 30% sucrose (in PBS). Spinal cords were freed
from underlying spinal columns by blunt dissection, embedded in OCT,
and rapidly frozen in dry ice-chilled isopentane. Serial transverse sec
tions from T13-S1 were cut at 12 μm thickness. To avoid repeat counts,
every 15th section was used for analysis. Following antigen retrieval,
sections were blocked for one hour in 5% donkey serum, 0.5% Triton X100, and 0.5% glycine (in PBS). Primary antibody incubation was done
overnight at 4 ◦ C with goat anti-ChAT antibody (1:100, Millipore, cat.
#AB144P) and rabbit anti-p53 antibody (1:1000, Leica Novacastra, cat.
# NCL-L-p53-CM5p). Secondary antibody incubations were performed
sequentially (each for three hours) at room temperature with Alexa
Fluor 594 donkey anti-rabbit antibody (1:250, Life Technologies, cat. #
A-11055) then Alexa Fluor 488 donkey anti-goat antibody (1:250, Life
Technologies, cat.# A-11029). Nuclei were stained with DAPI. Sections
were coverslipped using ProLong™ Diamond Antifade Mountant (Life

2.6. RNA preparation and qRT-PCR analysis
Animals were euthanized and tissues dissected at varying time
points. Total RNA was extracted using TRIzol reagent (Invitrogen) and
an RNeasy Mini kit (Qiagen, cat. #74106) according to the manufac
turer’s instructions. RNA concentration was determined using a Nano
Drop 2000 spectrophotometer (Thermo Scientific) and sample integrity
was confirmed by resolution of 28S and 18S rRNA bands in a 2:1 ratio,
respectively, by agarose gel electrophoresis. Samples were treated for
DNA contamination using Turbo DNase treatment (Invitrogen,
#AM1907) according to the manufacturer’s instructions and cDNA was
prepared from RNA using a High Capacity cDNA Reverse Transcription
kit (Life Technologies #4368814). qRT-PCR reactions were performed
with an ABI Quant Studio 3 thermocycler using TaqMan assays and fast
master mix (Life Technologies, cat. #4352042) in a 20 μl volume. Each
assay was performed at least in duplicate and biological replicates for
3
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Technologies, cat. # P36970) or Aqua-Mount (Lerner Laboratories, cat.
#13800). Images were acquired at 5× and 10× using a Leica DMR-HC
upright microscope; composite images were stitched using Image
Composite Editor (Microsoft). Spinal cord sections from end-stage (P12P15) Δ7 SMA mice treated in the same manner as above were included
as positive controls for p53 immunostaining.

Simon et al., 2017; Simon et al., 2019; Staropoli et al., 2015). Hence the
expression of several stress-associated transcripts [P21, Phorbol-12myristate-13-acetate-induced protein 1 (Pmaip1), Fas and Fas ligand (Fasl)]
was analyzed in whole spinal cord from pre-symptomatic (P5) to what
we considered end-stage disease (~P24-28) given the rapid disease
course thereafter (Supplemental Fig. 1). We found that P21 transcripts
from the earliest time point analyzed, P5, were already significantly
increased compared to control mice with a maximum activation at P12
[4.6 ± 0.8 (SMA) vs. 1.0 ± 0.2 (control)] that decreased over time but
remained significantly higher than controls. Generally, we found that all
transcripts analyzed (Pmaip1, Fas and Fasl), though not significantly
different at P5, had a similar trend of increasing over time in Smn2B/−
spinal cords compared to age-matched controls, peaking at P12; this
time point corresponds with the onset of overt symptomology in this
model. Pmaip1 was the most significantly increased [4.8 ± 0.3 (SMA) vs.
1.0 ± 0.1 (control)] at P12 and remained high (at 3.2-fold increase) at
end-stage disease. These results confirm similar findings in this model
and suggest that an increase in these transcripts are associated with an
increase in p53 signaling and may be associated with the onset of motor
neuron cell death (Courtney et al., 2019; Murray et al., 2015).
Activation of p53 and downstream target genes involved in cell death
pathways prominently occurs in spinal motor neurons of severe Δ7 SMA
mice; this extends to other spinal neuron populations as disease pro
gresses (Simon et al., 2017). To determine if this is also the case in
milder SMA mice, we compared p53 upregulation in Smn2B/− mice to
previous reports of p53 activation in Δ7 SMA mice using western blot
ting (Simon et al., 2017). We recapitulated the finding that p53 is
prominently upregulated (2.9-fold) in end-stage Δ7 SMA spinal cord
tissue compared to control (P = 0.0007) (Fig. 1A). Enhanced p53
expression was not observed in Smn2B/− whole spinal cord lysate at any
point during the disease course (Fig. 1B). As motor neurons represent
only a fraction of spinal cord cell types, we used immunohistochemistry
to specifically evaluate p53 expression in motor neurons. By immuno
fluorescence, we detected a significant increase in nuclear p53 expres
sion in Smn2B/− lumbar motor neurons compared to control
(P = 0.0285); Δ7 SMA mice were used as a positive control (Fig. 1C–D).
We were not able to determine if phosphorylation of p53 S18 marks
vulnerable motor neurons in Smn2B/− mice, as the antibody lots that
provided specificity for the Δ7 SMA mouse studies are no longer avail
able, and no other p53 S18 commercially available antibodies are
qualified for mouse studies. Overall, we determined that nuclear p53
immunoreactivity in non-motor neurons (ChAT-negative cells) was
markedly more abundant in end-stage Δ7 SMA mice compared to P16
Smn2B/− mice; this explains why p53 upregulation was undetectable in
Smn2B/− versus Δ7 SMA whole spinal cord lysate by western blotting.
Since spinal motor neurons of symptomatic (P16) Smn2B/− mice
expressed p53, we postulated that the p53 signaling pathway elicits
motor neuron loss in this model, as it does in Δ7 SMA mice (Simon et al.,
2017). To test this hypothesis, we bred the Trp53 null allele onto the
Smn2B/− background and determined if p53 depletion plays any role in
mitigating motor neuron loss.

2.9. Muscle weights and myofiber cross-sectional area (CSA) distributions
Quad, calf, and tibialis anterior (TA) muscles were dissected from
hindlimbs of P18 control (genotypes: Smn2B/+; P21+/+ and Smn2B/+;
P21− /− ), Smn2B/− ; P21+/+ and Smn2B/− ; P21− /− mice and weighed using
an analytical balance. Muscle weights were normalized to body weight.
Unless only one dissected muscle was intact, the left and right quad, calf,
and TA normalized muscle weights were averaged for analysis. Muscles
were fixed overnight in 2% paraformaldehyde at 4 ◦ C, rinsed in PBS, and
cryoprotected in 30% sucrose (in PBS). TA muscles from Smn2B/+; P21+/
+
, Smn2B/− ; P21+/+ and Smn2B/− ; P21− /− mice were dabbed dry,
embedded in OCT, and frozen on dry ice. Serial transverse sections from
muscle mid-belly were collected at 12 μm thickness. Sections were
rehydrated in PBS and blocked for 30 min in 5% goat serum, 0.5% Triton
X-100, and 0.5% glycine (in PBS). Primary antibody incubation was
performed overnight at 4 ◦ C with rabbit anti-dystrophin antibody
(1:250, Abcam, cat. # ab15277). After washing, sections were incubated
for two hours at room temperature in secondary antibody solution with
Alexa Fluor 594 goat anti-rabbit antibody (1:500, Jackson ImmunoR
esearch, cat. # 111–545-145). Nuclei were labeled with DAPI then slides
were coverslipped using ProLong™ Diamond Antifade Mountant (Life
Technologies, cat. # P36970). Images were acquired at 20× and 40×
with a Leica DM2500 upright microscope and stitched using Image
Composite Editor (Microsoft). TA myofiber CSAs were measured auto
matically (minimum detection threshold: 10 μm2) using ImageJ (NIH)
with minor manual editing. Myofibers that prominently deviated from
en face orientation, or were damaged or rolled, were excluded from
analysis.
3. Statistical analysis
All statistical analyses were performed using GraphPad Prism
(GraphPad Software, San Diego, CA). Survival data was represented
with Kaplan-Meier survival curves and statistically significant differ
ences between groups were evaluated using log-rank tests. Weight
curves were analyzed by mixed-model two-way ANOVA (with Tukey’s
tests for main column effects). For all other analyses, unpaired t-tests
(with Welch’s correction, in the event of unequal variances) ordinary
one-way ANOVA (with Tukey’s post-hoc tests), Brown-Forsythe and
Welch ANOVA tests (with Dunnett’s T3 multiple comparisons tests) in
the event of unequal variances, Kruskal-Wallis one-way ANOVA tests
(with Dunn’s post-hoc tests) in the event of nonparametric distributions,
or two-way ANOVA (with Tukey’s post-hoc tests) were performed as
needed. P-values <0.05 were considered statistically significant.

4.2. p53 depletion does not alter the timing of motor unit loss in Smn2B/−
mice

4. Results
4.1. p53 is upregulated in Smn2B/− motor neurons but not in whole spinal
cord lysate

We used an electrophysiological approach to determine if p53
depletion modulates the onset of motor unit loss in Smn2B/− mice.
Specifically, we measured sciatic compound muscle action potential
(CMAP) and motor unit number estimation (MUNE). Sciatic CMAP
magnitude reflects the amount and size of myofibers innervated by
motor axons comprising the sciatic nerve. Sciatic MUNE estimates the
number of motor axons, and therefore amount of functional motor
neurons, comprising the sciatic nerve (Arnold et al., 2015). We previ
ously reported that MUNE drops at P14 in Smn2B/− mice on an FVB/N
genetic background (Quinlan et al., 2019). Sciatic CMAPs of Smn2B/−
mice that were either wild type, heterozygous or homozygous null for

To investigate the p53 pathway in milder forms of SMA, we used
Smn2B/− mice in a C57BL/6 genetic background. In our laboratory, the
median survival has consistently been 28 days of age. After 28 days of
age, SMA mice rapidly progress so that ~25% are alive at 31 days with
maximum survival of 39 days (Quinlan et al., 2019). Since prior work
has shown that many genes upregulated in SMA motor neurons and
spinal cord tissues pertain to cellular stress and p53 pathway activation,
we sought to understand their transcriptional activation in Smn2B/− mice
throughout the disease course (Jangi et al., 2017; Murray et al., 2015;
4
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Fig. 1. p53 is upregulated in Smn2B/− and Δ7 SMA motor neurons. (A) Western blot analysis (left) and densitometric quantification (right) of p53 expression in spinal
cord lysate of end-stage Δ7 SMA mice (N = 3) and age-matched controls (N = 4) (P = 0.0007, unpaired t-test). Data are represented as mean ± SD. (B) Western blot
analysis (left) and densitometric quantification (right) of p53 in spinal cord lysate of P12-P32 Smn2B/− mice compared to age-matched controls (all P > 0.05, one-way
ANOVA, Tukey’s post-hoc tests). The “+” denotes lysate from doxorubicin-treated GL26-luc cells, that served as a positive control for p53 expression. Data are
represented as mean ± SD. (C) p53 activation and nuclear localization was observed in Smn2B/− lumbar spinal motor neurons using an immunohistochemical
approach (exemplified here at P16); Δ7 SMA motor neurons (shown here at P12) were used as a positive control comparator. White arrows indicate p53immunoreactive nuclei. (D) p53 nuclear immunoreactivity is significantly increased in lumbar (L4-L6) motor neurons of P16 Smn2B/− mice (P = 0.0285, unpaired
t-test). Implementation of Welch’s correction for unequal variances was used for t-tests when appropriate. For each boxplot, the outlined box represents the
interquartile range, the middle bar represents the median, and the error bars reach the minimum and maximum values. N = 5–6 per group.

Trp53 (Smn2B/− ; Trp53+/+, Smn2B/− ; Trp53+/− and Smn2B/− ; Trp53− /− )
were similar to that of control mice (Smn2B/+; Trp53+/+) at P12 and P14
(all P > 0.05), but were significantly reduced by P17-P18 (all P < 0.05)
(Fig. 2A). Further, CMAPs were comparable among Smn2B/− groups at
all time points (all P > 0.05), demonstrating that Trp53 knockout did not
rescue CMAP diminution in Smn2B/− mice. Moreover, MUNEs of all
Smn2B/− groups, regardless of Trp53 knockout status, were comparable

to control mice at P12, but were significantly decreased from P14 on
ward (all P < 0.05) (Fig. 2B). MUNEs were equivalent among Smn2B/−
cohorts (all P > 0.05). Therefore, functional motor unit loss first occurs
in C57BL/6 J Smn2B/− mice at P14 (which is equivalent to FVB/N Smn2B/
−
mice) and Trp53 knockout, neither heterozygous nor homozygous,
delayed its onset.
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Fig. 2. p53 depletion does not alter the timing of motor unit loss in Smn2B/− mice. (A) Compound muscle action potential (CMAP) schematic and measurements at
P12, P14 and P17-P18 for Smn2B/− ;Trp53 background. N = 3–10 mice per group. (B) Motor unit number estimation (MUNE) of mice at P12, P14 and P17-P18.
Schematic shows 10 incremental responses (in an SMA mouse). *P < 0.05, **P < 0.01 and ***P < 0.001. Statistical significance was determined using one-way
ANOVA with Tukey’s post-hoc tests for all datasets except P17-P18 time points, where Kruskal-Wallis one-way ANOVA tests (with Dunn’s post-hoc tests) were
used due to nonparametric distributions. Data are represented as mean ± SD.

4.3. p53 ablation does not mitigate Smn2B/− motor neuron loss

to the small sample size of Smn2B/− ; Trp53+/+ mice versus historical
Smn2B/− mice (N = 12 v. N = 35). However, median survival of Smn2B/− ;
Trp53− /− mice (P19) was drastically reduced compared to both Smn2B/− ;
Trp53+/+ littermates (P29) and historical Smn2B/− mice (P28), as well as
Smn2B/− ; Trp53+/− littermates (P24) (all P < 0.0001) (Fig. 4A–B). The
pronounced survival deficit conferred by p53 depletion was not driven
by diminished Smn expression, as Smn2B/− mice that were wild type and
homozygous null for Trp53 expressed equivalent Smn levels in spinal
cord tissue (P = 1.0) (Fig. 4C).
We next addressed whether reduced survival of Trp53-depleted
Smn2B/− mice could have been associated with an inability to obtain
nutrition, as we noted that some mice were runted. We assessed body
weights as a proxy for this. We first determined that Trp53 ablation did
not significantly alter growth curves by comparing weights of control
mice that were either wild type, heterozygous or homozygous null for
Trp53 (Fig. 4D). Since there were no differences, we pooled control mice
(genotypes: Smn2B/+; Trp53+/+, Smn2B/+; Trp53+/− and Smn2B/+;
Trp53− /− ) for further statistical analysis. As expected, growth curves of
all Smn2B/− groups, regardless of their Trp53 genotype, were signifi
cantly different from pooled controls (P < 0.0001). Interestingly, there
were no differences in growth curves or maximum body weights ach
ieved among the Smn2B/− ; Trp53 genotypes (Fig. 4E–F). However, when
historical Smn2B/− body weights were used as a comparator, we did
observe a difference between growth curves of historical Smn2B/− and
Smn2B/− ; Trp53+/− mice (P = 0.0147), but this had no effect on
maximum body weight achieved (Fig. 4F). In support of these results, we
note that mice of all SMA genotypes had milk in their stomachs, indi
cating that they were able to nurse until later stages of disease. Taken
together, these findings showed that Trp53 ablation modulated Smn2B/−
survival, but not weight. Further studies are necessary to identify the
underlying cause of the early mortality experienced by Trp53-depleted
Smn2B/− mice. Specifically, studies that determine whether the early
lethality is due to Trp53 ablation or potentially a modifier locus coming
from the 129S2 congenic interval on Chrm 11 that is linked to the Trp53
gene are warranted.

Diminished MUNE reflects motor neuron loss, motor axon dysfunc
tion, and neuromuscular junction denervation. To determine if p53depleted Smn2B/− motor neurons were denervated but not yet lost in
the spinal cord, we counted motor neurons in the spinal cord region
supplying the sciatic nerve, L4-L6. Consistent with MUNE results, we
found that homozygous Trp53 deletion did not attenuate spinal motor
neuron loss at P16 (Fig. 3). Both Smn2B/− ; Trp53+/+ and Smn2B/− ;
Trp53− /− mice had significantly fewer motor neurons per ventral horn
than their respective Smn2B/+ control group (P = 0.0076 and P = 0.0054,
respectively) (Fig. 3B). p53 depletion had no partial rescue effect: motor
neuron counts were comparable between Smn2B/− ; Trp53+/+ and Smn2B/
−
; Trp53− /− mice (P = 0.1521). Smn2B/− motor neurons populating both
medial and lateral motor columns were vulnerable to degeneration
(Fig. 3C–D). As expected, Smn2B/− ; Trp53− /− motor neurons did not
express p53 (Supplemental Fig. 2). Overall, these results demonstrate
that p53 ablation does not prevent Smn2B/− spinal motor neuron death
or lessen the degree to which they are lost.
4.4. Trp53 ablation exacerbates Smn2B/− survival but not body weight
We hypothesized that Trp53 deletion would extend Smn2B/− mouse
lifespan. Interestingly, we found that Trp53 knockout impaired survival
of Smn2B/− mice. The median survival of a prior cohort of C57BL/6 J
Smn2B/− mice in our colony (historical Smn2B/− mice) and Smn2B/− ;
Trp53+/+, Smn2B/− ; Trp53+/− , and Smn2B/− ; Trp53− /− mice was P28,
P29, P24, and P19, respectively (Fig. 4A–B). All Smn2B/− groups
exhibited diminished survival compared to pooled Smn2B/+ controls (all
P < 0.0001). Median survival of Smn2B/− ; Trp53+/+ mice was consistent
with that of historical Smn2B/− mice (P29 v. P28; P = 0.4713), reflecting
lack of genetic drift. Heterozygous Trp53 knockout significantly
impaired survival of Smn2B/− ; Trp53+/− mice (P24) compared to his
torical Smn2B/− mice (P28) (P = 0.0237), but not compared to Smn2B/− ;
Trp53+/+ littermates (P29) (P = 0.4907). This discrepancy is likely due
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Fig. 3. Trp53 ablation does not attenuate L4-L6 spinal motor neuron loss in Smn2B/− mice. (A) Representative coronal spinal cord sections from P16 Smn2B/+; Trp53+/
+
and Smn2B/+; Trp53− /− control mice (left) and Smn2B/− ; Trp53+/+ and Smn2B/− ; Trp53− /− SMA mice (right) immunostained for ChAT (green) and p53 (red), with
nuclei labeled by DAPI (blue). Medial (MMC) and lateral motor columns (LMC) are outlined in hashed lines. White arrow indicates a p53-immunoreactive nucleus.
(B) Quantitative analysis of total motor neurons per ventral horn. Smn2B/− ; Trp53+/+ and Smn2B/− ; Trp53− /− mice both exhibited motor neuron loss at P16, each with
fewer motor neurons per ventral horn than their respective controls (P = 0.0076 and P = 0.0054, respectively, unpaired t-test). Both medial (C) and lateral (D) motor
columns of Smn2B/− ; Trp53+/+ and Smn2B/− ; Trp53− /− mice had significantly fewer motor neurons compared to their respective controls (*P < 0.05, **P < 0.01,
unpaired t-test). Implementation of Welch’s correction for unequal variances was used for t-tests when appropriate. Data are represented as mean ± SEM; N = 3–6
mice per genotype.
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Fig. 4. Trp53 knockout impairs survival of Smn2B/− mice but does not alter their body weight. (A) Kaplan-Meier survival curve of Smn2B/− mice with Trp53 ablation.
Median survival of historical Smn2B/− mice and Smn2B/− ; Trp53+/+, Smn2B/− ; Trp53+/− , and Smn2B/− ; Trp53− /− mice was P28, P29, P24, and P19, respectively.
Survival was impaired in all Smn2B/− groups compared to Smn2B/+ controls (all P < 0.0001, log-rank test). Trp53 knockout further diminished survival of Smn2B/−
mice: survival of Smn2B/− ; Trp53− /− mice was significantly reduced compared to both Smn2B/− ; Trp53+/+ littermates and historical Smn2B/− mice as well as Smn2B/− ;
Trp53+/− siblings (all P < 0.0001, log-rank tests) and heterozygous Trp53 knockout significantly impaired survival of Smn2B/− ; Trp53+/− mice compared to historical
Smn2B/− mice (P = 0.0237, log-rank test). N = 76, N = 35, N = 12, N = 57, and N = 26 for Smn2B/+; Trp53+/+, Trp53+/− , Trp53− /− controls, historical Smn2B/− mice,
Smn2B/− ; Trp53+/+ mice, Smn2B/− ; Trp53+/− mice, and Smn2B/− ; Trp53− /− mice, respectively. (B) Scatter plots depicting the survival distribution of Smn2B/− mice
with Trp53 ablation (same Smn2B/− cohorts as analyzed in A). Data are represented as median ± interquartile range. (C) Western blot analysis (left) and densitometric
quantification (right) of Smn expression (normalized to β-tubulin) in spinal cord lysates of P17-P21 Smn2B/+ and Smn2B/− mice with and without Trp53 ablation
(N = 3–4 per group) were unchanged between Smn2B/+; Trp53+/+ mice and Smn2B/+; Trp53− /− mice and between Smn2B/− ; Trp53+/+ mice and Smn2B/− ; Trp53− /−
mice (P = 0.0875 and P = 1.0, respectively, one-way ANOVA, Tukey’s post-hoc tests). Both Smn2B/− groups exhibited Smn deficiency compared to Smn2B/+ control
groups (*P < 0.05, ***P < 0.001, one-way ANOVA, Tukey’s post-hoc tests). Data are represented as mean ± SD. (D) Trp53 knockout did not modulate postnatal day
(P)2-P21 Smn2B/+ mouse growth (all P > 0.05, mixed-model two-way ANOVA, Tukey’s tests for main column effect). N = 13, N = 47, and N = 16 for Smn2B/+; Trp53+/
+
mice, Smn2B/+; Trp53+/− mice, and Smn2B/+; Trp53− /− mice, respectively. Data are represented as mean ± SD. (E) Trp53 ablation did not improve Smn2B/− mouse
growth curves. Weight curves of Smn2B/− ; Trp53+/+, Smn2B/− ; Trp53+/− and Smn2B/− ; Trp53− /− mice bred in this study were comparable from P2-P21 (all P > 0.05,
mixed-model two-way ANOVA, Tukey’s tests for main column effect).The only significant difference found in Smn2B/− groups was altered body weight of Smn2B/− ;
Trp53+/− mice compared to historical Smn2B/− mice (P = 0.0147, mixed-model two-way ANOVA, Tukey’s test for main column effect). N = 33, N = 23, N = 57 and
N = 26 for historical Smn2B/− mice, Smn2B/− ; Trp53+/+ mice, Smn2B/− ; Trp53+/− mice, and Smn2B/− ; Trp53− /− mice, respectively. Data are represented as mean ± SD.
(F) Boxplots of maximum body weights reached by P18 historical and Smn2B/− mice that were wild type, heterozygous, or homozygous null for Trp53. ns;
nonsignificant, all P > 0.05, one-way ANOVA, Tukey’s post-hoc tests. For each boxplot, the outlined box represents the interquartile range, the middle bar represents
the median, and the error bars reach the minimum and maximum values. N = 33, N = 19, N = 53, and N = 23 for historical Smn2B/− mice, Smn2B/− ; Trp53+/+ mice,
Smn2B/− ; Trp53+/− mice, and Smn2B/− ; Trp53− /− mice, respectively.

4.5. P21 knockout does not rescue functional motor unit losses or spinal
motor neuron death in Smn2B/− mice

ChAT-immunofluorescence experiments demonstrated that reduced
MUNE of p21-depleted Smn2B/− mice reflected spinal motor neuron loss.
Compared to Smn2B/+; P21− /− littermates, Smn2B/− ; P21− /− mice had
significantly fewer motor neurons at P16 (P = 0.0250) (Fig. 5C–E).
Lateral motor neurons, which constitute the vast majority of motor
neurons in these spinal segments, largely contributed to this result;
Smn2B/− ; P21− /− mice had significantly fewer lateral motor neurons
than Smn2B+; P21− /− mice (P = 0.0064). There was a trend for reduced
numbers of medial motor neurons per ventral horn, but this did not
reach statistical significance (P = 0.2524) (Fig. 5F–G). We also noted
that Smn2B/− ; Trp53+/+; P21+/+ and Smn2B/− ; P21− /− motor neurons
had comparable levels of nuclear p53 immunoreactivity (P = 0.8437),
demonstrating that P21 ablation did not modulate p53 expression in
Smn2B/− ; P21− /− mice (Supplemental Fig. 2). Taken together, these re
sults demonstrate that p21 depletion, like p53 depletion, did not
ameliorate the timing or extent of Smn2B/− spinal motor neuron loss.

Prominent P21 (Cdkn1a) transcriptional upregulation, which is
present across tissues, is one of the most consistently reported findings in
differential gene expression studies using SMA models (Baumer et al.,
2009; Corti et al., 2008; Jangi et al., 2017; Murray et al., 2015; Olaso
et al., 2006; Ruggiu et al. 2012; Simon et al., 2017; Staropoli et al., 2015;
Tadesse et al., 2008; Wu et al., 2011; Zhang et al., 2008; Zhang et al.,
2013). It is a downstream transcriptional target of p53 but can also be
activated by other cellular stress signals. It is activated when cells are
damaged and can regulate cell survival or death. As a first step to un
derstand P21 transcriptional activation in Smn2B/− spinal cord tissue, we
measured P21 transcript abundance from pre-symptomatic to end-stage
of disease using qRT-PCR (Supplemental Fig. 1). We found that P21
transcripts were very slightly, but significantly, increased in P5 tissue.
This steadily increased during early disease but tapered as illness pro
gressed to end-stage (~P24-28). Surprisingly, p21 protein expression
was undetectable by western blot analysis using spinal cord extracts
from both control and Smn2B/− mice at P16 (Supplemental Fig. 3A).
However, using liver tissue from the same animals, we observed both
P21 mRNA and protein upregulation in Smn2B/− mice at P12 and P16,
but not in age-matched controls, or p21 knockout mice (Supplemental
Fig. 3B). This difference is most likely the result of ~2-fold higher
expression of P21 in liver at P12 and P16 versus spinal cord at P16 in
Smn2B/− mice, and the relative heterogenous versus homogenous nature
of the tissues. For example, Murray et al. (2015) have demonstrated that
P21 transcripts are more highly expressed in laser-captured motor
neurons compared to whole spinal cord tissue from Smn2B/− mice
(Murray et al., 2015).
To address whether P21 activation has a protective or detrimental
effect on spinal motor neuron loss and the neuromuscular phenotype of
Smn2B/− mice, we genetically ablated P21. Homozygous P21 knockout
mice are viable and fertile and were bred onto the Smn2B/− mouse
background. Crossing the P21 null allele onto the Smn2B/− line
frequently produced runts (both in controls and SMA mice), similar to
the Trp53 null allele. Like Trp53 depletion, neither heterozygous nor
homozygous P21 ablation rescued functional motor unit loss
(Fig. 5A–B). Sciatic CMAP and MUNE were reduced in P14 Smn2B/− ;
P21+/− and Smn2B/− ; P21− /− mice compared to Smn2B/+; P21+/+ con
trols (all P < 0.001). These measures were equally diminished in Smn2B/
−
; P21+/+, Smn2B/− ; P21+/− , and Smn2B/− ; P21− /− mice (all P > 0.05),
indicating that P21 knockout yielded no partial rescue effect.

4.6. P21 depletion extends survival of Smn2B/− mice but does not alter
body weight
Unlike Trp53 ablation, P21 ablation extended survival of Smn2B/−
mice. Median survival of historical Smn2B/− mice is 28 days. The median
survival of Smn2B/− ; P21+/+, Smn2B/− ; P21+/− , and Smn2B/− ; P21− /−
mice was P34, P33, and P37, respectively (Fig. 6A–B). There was no
significant difference between survival of our historical Smn2B/− mice
and Smn2B/− ; P21+/+ used here (P34 versus P28; P = 0.12). The trend for
enhanced survival of Smn2B/− ; P21+/+ mice likely reflects a small sample
size (N = 11) caused by preferential use of breeding schemes exclusively
generating Smn2B/+ and Smn2B/− mice with heterozygous and homozy
gous P21 knockout. Heterozygous P21 knockout significantly extended
survival of Smn2B/− ; P21+/− mice (P33) compared to historical Smn2B/−
mice (P28) (P = 0.0481), but not compared to Smn2B/− ; P21+/+ mice
(P34) (P = 0.9217). Homozygous P21 knockout on the SMA background
(Smn2B/− ; P21− /− ) significantly enhanced survival compared to histor
ical Smn2B/− mice (P < 0.0001) and Smn2B/− mice here that were wild
type or heterozygous null for P21 (P = 0.0462 and P = 0.0244, respec
tively). Notably, ~40% of Smn2B/− ; P21− /− mice lived for at least
40 days and ~ 9% more than doubled their lifespan, with the longest
surviving mouse reaching 101 days of age. This survival benefit
occurred through an Smn-independent mechanism, as Smn levels in
Smn2B/− ; P21− /− spinal cord tissue were equivalent to that of Smn2B/− ;
P21+/+ mice (P = 1.0) (Fig. 6C).
Although p21 ablation enhanced survival, it only slightly improved
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Fig. 5. P21 ablation does not mitigate functional motor unit losses and spinal motor neuron death in Smn2B/− mice. (A) Compound muscle action potential (CMAP)
and (B) motor unit number estimation (MUNE) were significantly diminished in Smn2B/− ; P21+/+, Smn2B/− ; P21+/− , and Smn2B/− ; P21− /− mice compared to Smn2B/+;
P21+/+ mice at P14. CMAP and MUNE were comparable among all Smn2B/− groups. ***P < 0.001, Brown-Forsythe and Welch ANOVA tests, Dunnett’s T3 multiple
comparisons tests; ****P < 0.0001, ordinary one-way ANOVA, Tukey’s post-hoc tests. Data are represented as mean ± SD. N = 6–8 mice per group. Representative
coronal spinal cord sections from (C) Smn2B/+; P21− /− control and (D) Smn2B/− ; P21− /− SMA mice immunostained for ChAT (green) and p53 (red), with nuclei
labeled by DAPI (blue). Medial (MMC) and lateral motor columns (LMC) are outlined in hashed lines. White arrow indicates a p53-immunoreactive nucleus. (E) Total
motor neurons per ventral horn were significantly less in Smn2B/− ; P21− /− mice compared to control Smn2B/+; P21− /− littermates at P16 (P = 0.0250, unpaired t-test).
(F) There was a trend for fewer medial motor neurons in Smn2B/− ; P21− /− mice, but this did not reach statistical significance (P = 0.2524, unpaired t-test); (G) lateral
motor neurons were significantly reduced in Smn2B/− ; P21− /− mice (P = 0.0064, unpaired t-test). Data are represented as mean ± SEM; N = 4–5 mice per genotype.

body weight curves of Smn2B/− mice during the pre-weaning period.
Generally, growth curves of Smn2B/− groups were similar, and there
were no differences in maximum body weights achieved by P18
(Fig. 6E–F). Starting at P18/19 and increasingly post-weaning, Smn2B/− ;
P21− /− mice weighed slightly more than both historical Smn2B/− mice
and Smn2B/− ; P21+/+ mice bred in this study. This timing coincides with
rapid disease progression experienced by Smn2B/− mice expressing wild
type P21. This later-stage weight disparity drove the overall weight
curve of Smn2B/− ; P21− /− mice to be significantly altered compared to
Smn2B/− ; P21+/+ counterparts (P = 0.0128 and P = 0.0077, respec
tively). Overall, P21 depletion did not correct body weight deficits of
Smn2B/− mice compared to controls, despite slight improvement of
Smn2B/− ; P21− /− mouse postnatal growth.

that p21 is not a significant transcriptional activator for Fas, Fasl, Pmaip1
or Pidd1, as there were no differences in transcript abundance when p21
was present or absent in Smn2B/− spinal cord. Further, the results suggest
that p53 is the primary driver of increased P21 transcripts early (at P12),
but as disease progresses, other transcriptional activators or modulators
of P21 transcript stability act independently of p53, as evidenced by the
significant increase in P21 transcripts at P16 in Smn2B/− ; Trp53− /− spinal
cord (Fig. 8). In contrast, we found, that Pidd1 transcripts in SMA spinal
cord were completely p53-regulated, as in its absence, Pidd1 transcripts
remained at control levels. Fas, Fasl and Pmaip1 were also positively
regulated by p53, as those transcripts returned to baseline control levels
at P12. However, similar to P21 transcripts, as disease progressed, these
transcripts increased in abundance, especially Pmaip1. In fact, at P16,
Pmaip1 transcripts were 4-fold higher than control samples. Collectively,
these data suggest that other transcriptional activators and pathways
besides p53 and p21 can induce expression of these genes which are
involved in cell death.

4.7. p21 ablation does not attenuate skeletal muscle atrophy
characteristic of Smn2B/− mice
p21 pathway activation in skeletal muscle is caused by a variety of
stimuli, including denervation. It induces atrophy by repression of
spermine oxidase (Smox), a positive regulator of muscle mass (Bongers
et al., 2015; Fox et al., 2014). Therefore, we hypothesized that inhibition
of muscle atrophy, caused by loss of p21, enhanced survival of Smn2B/− ;
P21− /− mice. To test this, we measured hindlimb skeletal muscle
weights and myofiber CSA distributions of P18 control, Smn2B/− ; P21+/+
and Smn2B/− ; P21− /− mice. We found that p21 depletion did not atten
uate muscle atrophy in Smn2B/− mice (Fig. 7). Average quad, calf, and
TA muscle weights (normalized to body weight) were reduced in both
Smn2B/− ; P21+/+ and Smn2B/− ; P21− /− mice compared to control (all
P < 0.05). p21 ablation had no effect on muscle size, as Smn2B/− ; P21− /−
normalized muscle weights were equivalent to that of Smn2B/− ; P21+/+
mice (all P > 0.05) (Fig. 7B–D). Furthermore, average CSAs of Smn2B/− ;
P21+/+ and Smn2B/− ; P21− /− TA myofibers were comparable
(P = 0.9605) and were smaller than that of Smn2B/+; P21+/+ mice
(P = 0.0132 and P = 0.0098, respectively) (Fig. 7E–F). Smn2B/− ; P21+/+
and Smn2B/− ; P21− /− myofiber CSA distributions were alike (Fig. 7G);
histogram analysis revealed that the only significant difference in bin
frequencies between Smn2B/− groups was a greater abundance of
51–100 μm2-sized myofibers in Smn2B/− ; P21− /− mice (P = 0.0075)
(Fig. 7H). Taken together, these results demonstrate that p21 knockout
did not mitigate skeletal muscle atrophy in Smn2B/− ; P21− /− mice.

5. Discussion
Identifying molecular mechanisms that mediate spinal motor neuron
degeneration and loss in SMA will allow these pathways to be targeted
therapeutically, yet these mechanisms remain unclear and debated. In
this study, we tested whether partial and complete genetic ablation of
p53 or p21 rescues functional motor unit losses, spinal motor neuron
death, and the SMA phenotype of Smn2B/− mice, which have a milder
disease course than Δ7 SMA mice. This is an important study, as p53 and
p21 are activated under cellular stress conditions; depending on the
severity of the stress, in one circumstance they may protect against cell
death, and in another circumstance evoke it. We determined that Trp53
and P21 knockout had opposing effects on Smn2B/− mouse survival and
neither meaningfully modulated body weight. Using immunohisto
chemical and electrophysiological approaches, we establish that Trp53
and P21 ablation did not modulate the onset or extent of Smn2B/− spinal
motor neuron death and functional losses. These results unequivocally
demonstrate that p53 and p21 are not primary drivers of spinal motor
neuron death in the Smn2B/− mouse model of SMA. This suggests that in
milder SMA mice, p53 and p21-independent mechanisms play an
important role in eliciting spinal motor neuron loss.
Our finding that Trp53 knockout fails to rescue Smn2B/− motor
neuron loss is consistent with recent work. Courtney et al. (2019) used a
tamoxifen-inducible cre-mediated recombination system to knockdown
Trp53 in Smn2B/− mice; tamoxifen dosing occurred at P4-P5, achieving
approximately 50% reduction in Trp53 transcript abundance. Trp53
reduction did not attenuate thoracic Smn2B/− motor neuron death at P15
(Courtney et al., 2019). Similarly, we demonstrated that heterozygous
Trp53 deletion did not mitigate onset or degree of lumbar Smn2B/− motor
neuron loss (at P14-P18). Further, we clearly show that homozygous
Trp53 ablation also does not protect against this loss (Figs. 2–3).
Together, these results indicate that spinal motor neuron death occurs
through a p53-independent mechanism in Smn2B/− mice. In general,
motor neurons belonging to both medial and lateral motor columns at
L4-L6 appeared similarly susceptible to degeneration in Smn2B/− mice,
but a stereology study evaluating individual spinal segments of a larger
number of animals at multiple time points across the disease course

4.8. Pmaip1 transcripts remain significantly elevated in the absence of
p53 and p21 in Smn2B/− spinal cord
Our results indicate that p53 and p21 are not the primary drivers of
motor neuron loss in Smn2B/− spinal cord. In the presence of these
proteins we saw that P21, Fas, FasL and Pmaip1 transcripts were
significantly elevated over the entire course of disease (P21) or pro
gressed to it. To determine if either p53 or p21 were the primary drivers
of these observed increases, we compared the abundance of these
transcripts in the presence and absence of these proteins at P12 and P16.
We also included Pidd1 (p53-induced-death-domain protein), also
known as LRDD, which is positively regulated by p53, involved in cell
death and we previously observed was significantly increased in the
spinal cords of Smn2B/− mice (Cherry et al., 2017). First, we determined
11
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Fig. 6. P21 knockout confers a significant survival benefit but does not rescue body weight deficits of Smn2B/− mice. (A) Kaplan-Meier survival curve of Smn2B/− mice
with P21 deletion. Median survival was P28, P34, P33, and P37 for historical Smn2B/− mice and Smn2B/− ; P21+/+, Smn2B/− ; P21+/− , and Smn2B/− ; P21− /− mice,
respectively. Survival was significantly reduced in all Smn2B/− groups compared to Smn2B/+ controls (all P < 0.0001, log-rank test), yet P21 ablation extended
survival of Smn2B/− mice: Smn2B/− ; P21− /− mice lived significantly longer than both Smn2B/− ; P21+/+ littermates and historical Smn2B/− mice as well as Smn2B/− ;
P21+/− siblings (P = 0.0462, P < 0.0001, and P = 0.0244, respectively) and heterozygous P21 knockout significantly improved survival of Smn2B/− ; P21+/− mice
compared to historical Smn2B/− mice (P = 0.0481, log-rank test). N = 54, N = 35, N = 11, N = 24, and N = 35 for Smn2B/+; P21+/+, P21+/− , P21− /− controls, historical
Smn2B/− mice, Smn2B/− ; P21+/+ mice, Smn2B/− ; P21+/− mice, and Smn2B/− ; P21− /− mice, respectively. (B) Scatter plot depicting the survival distribution of Smn2B/−
mice with P21 deletion (same Smn2B/− cohorts as analyzed in A). Data are represented as median ± interquartile range. (C) Western blot analysis (left) and
densitometric quantification (right) of Smn expression (normalized to β-tubulin) in spinal cord lysates of P16 Smn2B/+ and Smn2B/− mice with and without P21
ablation (N = 2–3 per group). Smn levels between Smn2B/+; P21+/+ mice vs. Smn2B/+; P21− /− mice and Smn2B/− ; P21+/+ mice vs. Smn2B/− ; P21− /− mice were similar
(P = 1.0 and P = 1.0, respectively, one-way ANOVA, Tukey’s post-hoc tests). Smn expression was significantly diminished in both Smn2B/− groups compared to
Smn2B/+ groups (**P < 0.01, one-way ANOVA, Tukey’s post-hoc tests). Data are represented as mean ± SD. (D) P21 ablation slightly altered Smn2B/+ postnatal
growth (between P2-P28). The weight curve of Smn2B/+; P21− /− mice was significantly altered compared to Smn2B/+; P21+/+ and Smn2B/+; P21+/− mice (P = 0.0241
and P < 0.0001, respectively, mixed-model two-way ANOVA, Tukey’s tests for main column effects). N = 9, N = 17, and N = 38 for Smn2B/+; P21+/+ mice, Smn2B/+;
P21+/− mice, and Smn2B/+; P21− /− mice, respectively. Data are represented as mean ± SD. (E) P21 ablation modulated growth rates within Smn2B/− groups. The
growth curve of Smn2B/− ; P21− /− mice was significantly different than Smn2B/− ;P21+/+groups (both P < 0.05, mixed-model two-way ANOVA, Tukey’s tests for main
column effects), exemplifying enhanced postnatal growth. *P < 0.05, **P < 0.01, ****P < 0.0001, mixed-model two-way ANOVA, Tukey’s test for main column
effects. N = 33, N = 14, N = 27 and N = 43 for historical Smn2B/− mice, Smn2B/− ; P21+/+ mice, Smn2B/− ; P21+/− mice, and Smn2B/− ; P21− /− mice, respectively. Data
are represented as mean ± SD. (F) Boxplots of maximum body weights reached by P18 historical and Smn2B/− mice that were wild type, heterozygous, or homozygous
null for P21. ns; nonsignificant, all P > 0.05, one-way ANOVA, Tukey’s post-hoc tests. For each boxplot, the outlined box represents the interquartile range, the
middle bar represents the median, and the error bars reach the minimum and maximum values. N = 33, N = 10, N = 24, and N = 35 for historical Smn2B/− mice,
Smn2B/− ; P21+/+ mice, Smn2B/− ; P21+/− mice, and Smn2B/− ; P21− /− mice, respectively.
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Fig. 7. P21 ablation does not ameliorate muscle atrophy in P18 Smn2B/− mice. (A) Scatter plots of P18 body weights. Both Smn2B/− ; P21+/+ and Smn2B/− ; P21− /−
mice weighed less than age-matched controls (P < 0.0001 and P = 0.0006, respectively, one-way ANOVA, Tukey’s post-hoc tests). Body weights of Smn2B/− ; P21− /−
and Smn2B/− ; P21+/+ mice were equivalent (P = 0.5783, one-way ANOVA, Tukey’s post-hoc test). Data are represented as mean ± SD. Mean (B) quad, (C) calf, and
(D) TA muscle weights (normalized to body weight) were diminished in Smn2B/− ; P21+/+ and Smn2B/− ; P21− /− mice compared to control (all P < 0.05, one-way
ANOVA, Tukey’s post-hoc tests). Smn2B/− ; P21− /− normalized muscle weights were comparable to that of Smn2B/− ; P21+/+ mice (all P > 0.05, one-way ANOVA,
Tukey’s post-hoc tests). N = 5–7 mice per group. Data are represented as mean ± SEM. (E) Transverse sections of TA muscle from P18 Smn2B/+; P21+/+ (left), Smn2B/
−
; P21+/+ (middle), and Smn2B/− ; P21− /− (right) mice immunostained for dystrophin (red), with nuclei labeled by DAPI (blue). (F) Mean myofiber CSA was reduced
in both Smn2B/− ; P21+/+ and Smn2B/− ; P21− /− TA muscles compared to that of Smn2B/+; P21+/+ (P = 0.0132 and P = 0.0098, respectively, one-way ANOVA, Tukey’s
post-hoc tests). Mean myofiber CSA of Smn2B/− ; P21+/+ and Smn2B/− ; P21− /− muscles were equivalent (P = 0.9605, one-way ANOVA, Tukey’s post-hoc test). >1750
myofibers were analyzed per mouse; N = 3 mice per group. Data are represented as mean ± SEM. (G) Violin plots of myofiber CSA distributions in P18 TA muscles.
For each violin plot, the hashed line indicates the median, the dotted lines represent interquartile range, and the outer shape depicts the kernel density estimation.
(H) Histograms depicting myofiber CSA distributions in P18 TA muscles. Shown are statistics comparing bin frequencies for Smn2B/− ; P21+/+ and Smn2B/− ; P21− /−
mice. Frequency distributions were highly similar between Smn2B/− ; P21+/+ and Smn2B/− ; P21− /− mice: the only significant difference was a greater frequency of
51–100 μm2-sized myofibers in Smn2B/− ; P21− /− mice (P = 0.0075, two-way ANOVA, Tukey’s post-hoc test). Data are represented as mean ± SD.
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Fig. 8. Effect of p53 or p21 deficiency on gene transcripts involved in cellular stress and cell death. Transcript abundance of P21 (Cdkn1a), Pmaip1, Fas, Fasl and
Pidd1 were analyzed at P12 and P16 in control (Smn2B/+) and SMA (Smn2B/− ) genotypes with and without p53 or p21. Statistical analyses were performed using oneway ANOVA for all transcripts except Fas. Fas was statistically analyzed using Brown-Forsythe and Welch ANOVA tests (with Dunnett’s T3 multiple comparisons
tests) since variances were significantly different between groups. The data is presented as mean normalized relative mRNA expression ± SD. N = 3–4 mice per group.
(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant).

would clarify the phenomenon of preferential vulnerability in this
mouse model.
Using the more severe Δ7 SMA mouse model, Simon et al. (2017)
reported that SMN deficiency triggers p53 activation early in vulnerable
motor neuron pools; resistant motor neuron pools and other (non-motor
neuron) cell types that to not degenerate exhibit widespread p53 acti
vation only at later stages of the disease (Simon et al., 2017). They
provide compelling evidence that phosphorylation of specific serines in
the amino-terminal transactivation domain (TAD) of p53 is necessary to
trigger death of vulnerable Δ7 SMA motor neurons, identifying phos
phorylation of p53 serine 18 as a death-specific marker that selectively
occurs in vulnerable SMA motor neurons. They demonstrated the
specificity of these findings using pharmacological inhibition of p53 and
shRNA-mediated Trp53 gene silencing to rescue loss of vulnerable spinal
motor neurons in Δ7 SMA mice; resistant motor neurons are not lost
during the short lifespan of that mouse (Simon et al., 2017). Interest
ingly, Nichterwitz et al. (2020) recently demonstrated that both resis
tant (ocular) and vulnerable (spinal) motor neurons of Δ7 SMA mice
upregulate the p53 signaling pathway, signifying cellular stress in both
of these somatic motor neuron populations, while resistant neuronal
populations (red nucleus neurons and visceral vagus motor neurons) do
not exhibit this cellular stress signature (Nichterwitz et al., 2020). The
discrepancy between these findings in severe Δ7 SMA mice and our
results, plus that of Courtney et al. (2019), suggests that p53 pathway
activation (and p53 serine 18 phosphorylation) is necessary to induce
motor neuron death in the Δ7 SMA mouse model, but not in the slightly
milder Smn2B/− mouse model.

Whether p53 induces pro-survival or pro-apoptotic downstream ac
tivity in response to a cellular insult depends on the severity of the
cellular stress (Levine and Oren, 2009). Δ7 SMA motor neurons may
experience stronger cellular stress than Smn2B/− motor neurons, leading
p53 to evoke cell death in the former but not the latter. p53 upregulation
in Smn2B/− motor neurons might instead drive protective mechanisms
that ultimately fail. The idea of differential cellular stress in these two
models is further supported by the timing of motor unit loss (~ one week
apart in the models) (Arnold et al., 2014; Quinlan et al., 2019) and the
lack of p53 activation that is seen by western blot in Smn2B/− SMA mice
versus Δ7 SMA mice. Our findings considered in the broader context of
recent reports discussed above, suggest that in patients, spinal motor
neuron loss may occur through different molecular mechanisms
depending on the severity of SMA clinical symptoms.
Although Trp53 ablation did not modulate Smn2B/− motor neuron
loss, it had a radical effect on Smn2B/− mouse survival. Homozygous
Trp53 knockout shortened the lifespan of Smn2B/− ; Trp53− /− mice by
10 days when comparing their median survival to Smn2B/− ; Trp53+/+
littermates (P19 v. P29; P < 0.0001) (Fig. 4A–B). Since Smn expression
itself (Fig. 4C) and motor neuron viability (Figs. 2–3) were unmodified
in Smn2B/− ; Trp53− /− mice, their impaired survival was likely associated
with p53 depletion in other cell types. During tissue harvests, we noted
that Trp53-depleted Smn2B/− mice appeared to have more severe fatty
liver and intestinal dysfunction. It is possible that Trp53 ablation in the
liver of Smn2B/− ; Trp53− /− mice resulted in their early demise. Smn2B/−
mice develop impaired fatty acid metabolism and progressively accu
mulate fat in the liver (termed hepatosteatosis), resembling non14
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alcoholic fatty liver disease (NAFLD) (Deguise et al., 2019). Addition
ally, Smn2B/− mice become hypoglycemic (Deguise et al., 2019), and
progressive motor dysfunction likely renders late-stage Smn2B/− mice
malnourished. However, we noted that all Smn2B/− mice, regardless of
Trp53 knockout status, had milk in their stomachs until end-stage of
disease. It could be that p53 ablation exacerbated metabolic defects in
Smn2B/− mice, driving their premature death. Indeed, adult Trp53 null
mice, and mice with liver-specific p53 knockdown, exhibit hep
atosteatosis (Jiang et al., 2011; Porteiro et al., 2017; Prokesch et al.,
2017; Wang et al., 2013). Chronic, low-dose doxorubicin treatment at
tenuates hepatosteatosis in NAFLD mice; p53 mediates this attenuation,
as doxorubicin treatment failed to ameliorate hepatosteatosis in mice
with liver-specific p53-knockdown (Porteiro et al., 2018). Furthermore,
in response to food withdrawal, adult mice with liver-specific p53knockdown become hypoglycemic (reflecting defective glucose ho
meostasis) and exhibit impaired hepatic amino acid catabolism (Pro
kesch et al., 2017). Taken together, it is probable that p53 depletion in
Smn2B/− mice aggravated liver pathologies, including abnormal fatty
acid metabolism and hepatic gluconeogenesis, further impairing their
survival. It is also possible that reduced survival is due to a semidominant 129S2 modifier on Chrm 11 linked to the Trp53 gene, which
we are unable to rule out with these studies. Modifiers are known to exist
for SMA and if a modifier did impact survival, it could be specific to liver
function or elsewhere.
p53 and other upstream regulators (e.g., Sp1, AP2, and STATs)
transactivate P21 in cellular stress conditions (Gartel and Tyner, 1999;
Gorospe et al., 1999; Piccolo and Crispi, 2012). Nuclear subcellular
localization enables cell cycle arrest functions of p21, whereas cyto
plasmic subcellular localization enables further p21-mediated regula
tion of cell survival independent of its CDK-inhibitory activity (Cmielova
and Rezacova, 2011; Janicke et al., 2007). In a context-dependent
manner, p21 mediates both pro-apoptotic and pro-survival signaling
relays through p53-dependent and p53-independent mechanisms (Gar
tel, 2005; Gartel and Tyner, 2002). Although p21 is primarily associated
with cell survival responses, evidence for p21’s role in driving cell death
has emerged (Gartel and Tyner, 2002; Gorospe et al., 1999). Over
expression of p21 has been shown to: (1) induce apoptosis in human
cervical cancer, breast carcinoma, and glioma cell lines (Kondo et al.,
1996; Sheikh et al., 1995; Tsao et al., 1999); (2) enhance ceramideinduced apoptosis in human hepatocarcinoma cells through upregula
tion of Bax (Kang et al., 1999); and (3) induce apoptosis in differenti
ating murine 32Dcl3 myeloblasts upon IL-3 withdrawal (Ghanem and
Steinman, 2005). An additional early study demonstrated that P21
ablation in mouse thymocytes (co-cultured with Fas-ligand-expressing
fibroblasts) attenuated Fas-ligand-mediated apoptosis through a p53independent mechanism (Hingorani et al., 2000). Moreover, p21 asso
ciates with and inhibits the anti-apoptotic transcription factors NFκB
and STAT3, which may promote apoptosis (Coqueret and Gascan, 2000;
Janicke et al., 2007; Khanna et al., 2005). On the other hand, p21 exerts
anti-apoptotic functions by associating with and inhibiting proapoptotic proteins. These targets include procaspase 3, caspase 8, and
ASK-1, an upstream activator of Jun N-terminal kinase (JNK) (Abbas and
Dutta, 2009; Asada et al., 1999; Ichijo et al., 1997; Suzuki et al., 1998;
Xu and El-Deiry, 2000). Kitaura et al. (2000) demonstrated that p21
suppresses transcriptional activity of c-myc, which might prevent c-mycmediated apoptosis (Janicke et al., 2007; Kitaura et al., 2000). Lastly,
p21 induces expression of secreted anti-apoptotic proteins such as
galectin-3 and prosaposin, and addition of conditioned media from p21induced cells attenuated apoptosis in embryonic mouse fibroblast cells
(Chang et al., 2000; Dotto, 2000). In this study, we determine that P21
deletion, like Trp53 deletion, did not change the timing or degree of
Smn2B/− spinal motor neuron loss (Fig. 5). These results demonstrate
that p21 is not necessary to induce Smn2B/− motor neuron death. Rather
than inducing cell death, P21 upregulation in Smn2B/− motor neurons
may instead signify a protective response to cellular stress that is ulti
mately ineffective.

Although P21 is a well-established transcriptional target of p53, we
found that Trp53 ablation reduced P21 transcript levels to baseline at
P12 in Smn2B/− ; Trp53− /− mouse spinal cords, but increased with age at
P16 (Fig. 8). This result signifies P21 transcriptional activation by up
stream regulators other than p53 or potentially modulation of P21
transcript stability by regulators such as KRSP, which is dysregulated in
SMA (Briata et al., 2005; Tadesse et al., 2008). In addition to p53,
numerous other transcription factors induce P21 expression in response
to cellular stress (Gartel and Tyner, 1999; Gorospe et al., 1999). These
include: (1) Sp1 and FoxO proteins (in complex with Smad proteins), in
response to the cytokine TGF-β (Pardali et al., 2000; Seoane et al., 2004;
Zhang et al., 2017); (2) BRCA1, in response to DNA damage (Mullan
et al., 2006); (3) members of the Sp1 transcription factor family, (coactivated by p300/CBP) in response to increased intracellular calcium
(Missero et al., 1995); (4) AP-2, in response to the phorbol ester tumor
promoter, 12-O-tetradecanoylphorbol 13-acetate (TPA) (Zeng et al.,
1997); (5) C/EBP-β, in response to antioxidants (Chinery et al., 1997);
(6) STATs, in response to the cytokines IFN-α, IL-6, and thrombopoetin
(Bellido et al., 1998; Gorospe et al., 1999; Hobeika et al., 1997; Mat
sumura et al., 1997); and (7) neuronally expressed JAZ, in response to
oxidative stress, potassium deprivation-induced neuronal death, and
proteinopathies (Mallick and D’Mello, 2014). Numerous additional p53independent factors induce P21 expression (in various conditions),
including: retinoic acid, vitamin D, vitamin E, androgen, C/EBP-α, GAX,
HOXA10, MAPK, nerve growth factor, epidermal growth factor, pro
gesterone, NeuroD, and MyoD1 [reviewed in (Gartel and Tyner, 1999)
and (Abbas and Dutta, 2009)]. Cellular stress unfolding in Smn2B/− ;
Trp53− /− spinal cords with age likely evokes P21 transcription through
one or more p53-independent molecular pathways.
Although p21 ablation did not alter Smn2B/− motor neuron viability
(Fig. 5) or muscle atrophy (Fig. 7), it considerably extended the lifespan
of Smn2B/− mice through mechanisms that did not alter Smn levels
(Fig. 6A–C). Notably, ~13% of Smn2B/− ; P21+/− mice and 40% of
Smn2B/− ; P21− /− mice lived to P40, whereas no Smn2B/− ; P21+/+ lit
termates or historical Smn2B/− mice did. There are two potential in
terpretations for this. First, that p21 ablation imparts a survival benefit
to Smn2B/− mice through attenuation of pathologies that most likely
exist outside the neuromuscular system. However, we performed these
analyses at P18 and earlier, and interestingly it is after this age that
weight loss in homozygous P21-null Smn2B/− mice is not as drastic as
either wild type or heterozygous P21-null Smn2B/− mice. Hence it would
be interesting to determine if P21 ablation improves muscle mass in SMA
models less severe than Smn2B/− mice. The second interpretation for the
observed survival benefit could be a modifier locus, which we cannot
rule out in the current study. It is possible that a survival modifier is
contained within the 129S6 congenic interval on Chrm 17 that contains
the P21 knockout allele, or that a negative modifier was lost from the
C57BL/6 background that was present in the region. Again, like Trp53, it
would be very interesting to know what drives survival either in a
negative or positive manner as these are potentially important thera
peutic targets. Overall, our work indicates that the primary molecular
mechanisms eliciting Smn2B/− motor neuron loss are different than those
driving motor neuron loss in Δ7 SMA mice with a more severe neuro
muscular phenotype. This is based on our main finding that Smn2B/−
motor neuron death proceeds with the same timing and degree in the
absence of p53, while p53 pathway inhibition clearly rescues Δ7 SMA
motor neuron loss (Simon et al., 2017). Therefore, it is critical to
consider where each SMA model system falls along the disease severity
spectrum when studying molecular mechanisms of spinal motor neuron
dysfunction and death. Moreover, additional studies investigating up
stream regulators of spinal motor neuron loss in mouse models milder
than Δ7 SMA mice are needed. An additional signaling pathway impli
cated in initiating Δ7 SMA motor neuron loss is the JNK signaling
pathway, as both Jnk3 knockout and pharmacological treatment with a
JNK-inhibitor peptide attenuated the SMA phenotype of Δ7 SMA mice
(Genabai et al., 2015; Schellino et al., 2018). Studies testing
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involvement of the JNK signaling pathway in Smn2B/− motor neuron
death have not been done, but are warranted, since in the absence of
p53, Fas and Fasl increases were noted and they are part of the extrinsic
apoptotic pathway regulated by JNK signaling. Similarly, earlier work
has identified Fas-ligand-mediated apoptosis in iPSC-derived motor
neurons from Type I SMA patients (Sareen et al., 2012), yet Fas-ligandmediated apoptosis is unexplored in Smn2B/− mice. In addition to these,
deficiency in DNA damage repair complexes has been reported in both
Δ7 and Smn2B/− SMA mice, providing another pathway that should be
further investigated (Kannan et al., 2018; Murray et al., 2015). Further,
we show here that Pmaip1, which is part of the intrinsic apoptotic
pathway, is independently activated in the absence of p53 and would be
another excellent target to further evaluate. Overall, the alternative
signaling pathways driving Smn2B/− spinal motor neuron death remain
to be identified and will have significant implications for supplemental
SMA therapies.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.expneurol.2020.113587.
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